Adma biologics inc ADMA.US 總覽分析

美股醫療保健
(ADMA 無簡報檔)

ADMA 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上

ADMA 近期報酬表現

2.35%

Adma biologics inc

4.57%

同產業平均

3.26%

S&P500

與 ADMA 同產業的標的表現

  • HALO Halozyme therapeutics, inc.
    價值 5 分趨勢 4 分波段 4 分籌碼 3 分股利 1 分
    查看更多

ADMA 公司資訊

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

ADMA 股價